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Abstract
Purpose—African American women are more likely to be diagnosed with metastatic breast 
cancer at the time of presentation than whites, and have shorter survival once diagnosed. This 
study examines racial differences in clinical outcomes in the setting of two large cooperative group 
randomized clinical trials.
Patients and Methods—The study cohort consisted of 787 white (80%) and 195 African 
American (20%) patients with metastatic breast cancer enrolled in two successive Cancer and 
Leukemia Group B (CALGB) trials using taxanes in the metastatic setting. Differences in overall 
survival (OS), response incidence, and time to treatment failure (TTF) were examined by race. In 
addition, differences in the incidence of baseline and treatment-related toxicities were examined.
Results—With 779 deaths (166 African Americans and 613 whites), median OS was 14.3 
months for African Americans and 18.75 months for whites (hazard ratio [HR] = 1.37; 95% CI, 
1.15 to 1.63). When adjusted for prognostic factors, African Americans had a 24% increase in the 
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hazard of death compared with whites (HR = 1.24; 95% CI, 1.02 to 1.51). No significant 
differences in TTF or overall response to therapy were seen. No clinically significant toxicity 
differences were seen.
Conclusion—African Americans with metastatic breast cancer have an increased hazard of 
death compared with whites despite the receipt of similar per-protocol treatment, but experience 
no differences in TTF or overall response to therapy. We hypothesize that more direct and robust 
measures of comorbidities, and perhaps other factors such as receipt of subsequent therapy could 
help further explain the observed survival difference.
INTRODUCTION
It is well established that African American women have a lower incidence of but higher 
mortality rate from breast cancer than whites.1,2 Much of this survival disparity has been 
attributed to more advanced stage at diagnosis.3 Although differences in stage at diagnosis 
are important in understanding the survival disparity, even when analyses are controlled for 
stage, African Americans continue to have poorer long-term survival rates. The 5-year 
relative survival for patients diagnosed with metastatic disease between 1996 and 2002 was 
28% for whites and only 16% for African Americans. Of particular concern is that this 
survival disparity is growing compared with the 1975 to 1979 period, when the 5-year 
cancer-specific survival was 18% for whites and 15% for African Americans.2
Understanding this stage-specific survival disparity is challenging. Previous researchers have 
pointed to racial differences in tumor-related factors such as hormone-receptor status and 
tumor histology.3–6 Others have explored the importance of patient-related characteristics 
such as socioeconomic status and competing comorbidities among African American 
women.3,7–9 Finally, treatment-related factors such as inadequate therapy or higher rates of 
toxicity, perhaps leading to lower intensity of treatment, have been explored as reasons for 
the poorer stage-specific survival for African American women.10–15
One way to analyze and isolate the reasons for stage-specific survival differences is to look 
at outcomes in the setting of a clinical trial. The advantage of analyzing clinical trial data is 
that eligibility criteria, treatments, and response data are standardized and quantified. Also, 
information on tumor biology, treatment-related toxicities, and some patient-related 
characteristics are prospectively collected and can be analyzed to determine whether they 
have an impact on observed racial differences in survival. This type of analysis has been 
performed in patients with nonmetastatic breast cancer with several cooperative group 
studies and demonstrated no differences in breast cancer–specific survival between African 
Americans and whites after adjusting for demographic and prognostic tumor variables.16–18 
However, analysis of the Southwest Oncology Group (SWOG) adjuvant breast cancer trials 
did find that African Americans had lower overall survival (OS) and cancer-specific survival 
compared with whites even after controlling for demographics and prognostic tumor 
variables.19 In the metastatic breast cancer setting, no large cooperative group analysis has 
been performed. A small study of metastatic breast cancer patients participating in five 
Piedmont Oncology Association trials found no difference in response rates between African 
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Americans and whites; however, white patients had a statistically significant 6-month longer 
median survival.20
The metastatic breast cancer setting offers a unique setting to explore racial differences in 
survival in that the analysis begins at time when all patients are established to have incurable 
disease. In this analysis, we examined racial differences in clinical outcomes and the 
potential reasons behind those differences in the setting of two large cooperative group 
metastatic breast cancer trials.
PATIENTS AND METHODS
Study Population
The study cohort consisted of patients enrolled in Cancer and Leukemia Group B (CALGB) 
trials 9342 and 9840. Details of these trials have been reported previously.21,22 In brief, 
between January 15, 1994, and July 31, 1997, CALGB 9342 randomly assigned patients 
with measurable metastatic breast cancer or inoperable breast cancer and zero to one prior 
treatments for locally advanced or metastatic disease to three different doses of paclitaxel 
(175 mg/m2, 210 mg/m2, or 250 mg/m2) administered over 3 hours every 3 weeks. Between 
January 15, 1998, and November 14, 2003, CALGB 9840 randomly assigned patients with 
measurable metastatic breast cancer and zero to one prior chemotherapy regimens for locally 
advanced or metastatic breast cancer to paclitaxel 175 mg/m2 administered every 3 weeks or 
paclitaxel 100 mg/m2 administered weekly. Weekly dose was subsequently amended to 80 
mg/m2. Patients with HER-2–positive tumors (immunohistochemistry 3+) received 
trastuzumab; patients with HER-2–negative tumors (immunohistochemistry 0 to 2+) were 
randomly assigned to receive trastuzumab or not. After excluding 61 patients who were 
neither white nor African American and 13 patients with unknown ethnicity, the final cohort 
consisted of 787 white and 194 African American patients.
Statistical Analysis
The primary study end points were tumor response, OS, and time to treatment failure (TTF). 
OS was calculated as the time from study entry to date last known alive or to date of death 
resulting from any cause. TTF was measured from study entry to date of first disease 
progression or to date of death for those patients who died without progression. Patients who 
were alive and without progression were censored at the date they were last known to be 
progression free. Tumor response was defined as complete or partial response. Complete 
response was defined as the disappearance of all lesions. Partial response was defined as a 
reduction of at least 50% of the sum of the product of all lesions with bidimensional 
measurements, and with stable or improving nonmeasurable lesions. Patients whose tumors 
could not be assessed for response because of excessive toxicity or early death were 
considered nonresponders.
Logistic regression was used to model the relation of tumor response with race and other 
covariables.23 Proportional hazards regression was used to model the relation of OS and 
TTF, respectively, with race and other covariables.24 Each of the two clinical trials whose 
populations are included herein was stratified by line of therapy. Therefore all models 
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include indicator variables for line of therapy and for study. For each end point, we 
constructed two sets of models. The base model included race, study and line of therapy. In 
addition to the variables in the base model, the full model included other covariables. To 
assess the relation of race on time to onset of selected toxicity with a severity of at least 
grade 3, we constructed proportional hazards regression models for each toxicity that had at 
least a 20% incidence of grade 3 or higher severity. We used the National Cancer Institute 
Common Toxicity Criteria version 2.0 to grade toxicity.
Covariables of interest were patient demographics (age, menopausal status), 
clinicopathologic features (tumoral estrogen-receptor [ER] status, number of measurable 
metastatic sites, performance score, prior adjuvant therapy, pretreatment blood counts) and 
treatment factors (dose schedule and paclitaxel dose) available at study entry. Race was 
determined by patient self-report. The following variables were analyzed as dichotomous 
variables: race (African American v white), study (9342 v 9840), line of therapy (first v 
second), ER status (negative v positive), menopausal status (pre v post), prior adjuvant 
therapy (yes v no), and dose schedule (weekly v standard). Paclitaxel dose (80, 100, 175, 
210, 250), performance score (0 to 3) and patient age were analyzed on a continuous scale. 
Other variables were transformed, as follows: (1) square root:number of measurable 
metastatic sites and (2) log10:WBC, platelets and granulocytes.
Main effects were assessed in multivariate regression models using the Wald χ2 test. Odds 
ratios (ORs) and hazards ratios (HRs) for main effects and their respective 95% CIs were 
taken from the corresponding regression model. ORs and their 95% CIs for interaction terms 
were calculated using the method of Hosmer and Lemeshow.23
OS, TTF, and time to toxicity distributions were estimated using the Kaplan-Meier product 
limit technique.24 We used the χ2 test to compare two proportions and the Mann-Whitney U 
test to compare two groups on continuous variables. Analyses used a modified intention-to-
treat approach, including all patients who began protocol therapy regardless of eligibility 
determination. There was a 5% ineligibility incidence in each racial subgroup.
All P values are two sided. We report as significant P ≤ .05. CALGB statisticians performed 
statistical analyses on data available in the CALGB database as of February 2005 using SAS 
9.1 (SAS Institute, Cary, NC).
RESULTS
Race in Relation to Other Patient and Disease Characteristics at Study Entry
The study population included 787 white (80%) and 195 African American (20%) patients. 
Table 1 shows patient and disease characteristics and treatment variables by race and line of 
therapy. Fifty-one percent of African American patients compared with 41% of white 
patients were receiving second line therapy for metastatic breast cancer (P = .014). 
Restricting to line of therapy, a larger proportion of African American patients than white 
patients were younger (first line, P < .0001; second line, P = .0050) and premenopausal (first 
line, P = .0004; second line, P = .033). Additionally, a higher proportion of African 
American patients had ER-negative tumors (first line, P = .0045; second line, P = .055). At 
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study entry African Americans had significantly lower hemoglobin levels (first line, P = .
0001; second line, P = .0021) and significantly higher platelet counts (first line, P = .0001; 
second line, P = .0057) than their white counterparts.
Influence of Race on Tumor Response, OS, and TTF
Observed effect: Base models—African American patients had a median OS of 14.3 
versus 18.7 months for white patients. African American patients had a median TTF of 4.9 
versus 6.4 months for white patients. This translates into a 37% increase in the hazard of 
death (HR = 1.37; 95% CI, 1.15 to 1.63) for African American patients and a 17% increase 
in the hazard of failure (HR = 1.17; 95% CI, 0.99 to 1.38) for African American patients 
over white patients. Tumor response did not differ by race overall (30% v 31%). The results 
are shown in Table 2. The Kaplan-Meier curves for OS and TTF are shown in Figures 1 and 
2.
Adjusted observed effect: Full models—Table 3 shows the observed effect of race on 
OS and TTF after adjusting for all predictor variables. African American patients continue to 
have an increased hazard of death compared with whites, albeit of a lower magnitude than 
seen in the base model (HR = 1.24; 95% CI, 1.02 to 1.51; P = .030). The effect of race on 
TTF remains nonsignificant (HR = 1.11; 95% CI, 0.92 to 1.33; P = .29). In addition to race, 
other variables significantly related to survival were study, line of therapy, ER status, 
performance score, pretreatment platelet count, and age. Other variables significantly related 
to TTF were study, performance score, age, ER status, number of metastatic sites at 
enrollment, and dosing schedule.
Influence of Race on Treatment-Related Toxicities
Table 4 shows the incidence of grade 3+ selected toxicities by race. Compared with white 
patients, African American patients had a significantly higher incidence of anemia (8% v 
3%) and a slightly higher incidence of thrombocytopenia (2% v < 1%) and neutropenia 
(42% v 35%). No differences were seen with respect to grade 3+ leucopenia, 
lymphocytopenia, infection, or neuropathy.
In total, 20% or more of all patients experienced grade 3 or higher leucopenia, neutropenia, 
and lymphocytopenia. We assessed the relation of race, after adjusting for study and line of 
therapy, with time to onset of grade 3+ of each of these three toxicities. Compared with 
African American patients, white patients had a slightly higher hazard of developing grade 
3+ lymphocytopenia (HR = 1.30; 95% CI, 1.00 to 1.69; P = .048). Time to onset of grade 3+ 
leucopenia or neutropenia did not differ by race (data not shown).
DISCUSSION
Consistent with national epidemiologic data, we found that African Americans participating 
in these two large cooperative group meta-static breast cancer trials have a shorter OS than 
white patients. We did not, however, see any significant difference in response to therapy or 
TTF by race. The advantage of clinical trial data is that eligibility and treatment are 
standardized and several known prognostic tumor and patient-related factors are 
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prospectively collected and can be accounted for in the analyses. However, even after 
adjusting for these factors, a persistent survival disparity was seen. The critical question is, 
why?
Race is a complex variable that is likely acting as a proxy for factors associated with lower 
socioeconomic status, culture, discrimination, and other factors. In addition the potential that 
race is also serving as surrogate for underlying differences in tumor and host biology cannot 
be dismissed. Any time survival differences by race are documented in the presence of what 
seems to be equal treatment, the issue of potential differences in underlying tumor and 
patient biology surfaces. Previous studies have documented racial differences in tumor 
biology such as hormone-receptor status, tumor grade, and S-phase fraction, which may lead 
to a more aggressive tumor phenotype in African Americans versus whites.6,10,25,26 Indeed, 
a subset analysis of patients enrolled on CALGB 9342 suggests that African American 
patients were more than twice as likely to have so called triple-negative tumors (ER, 
progesterone receptor, and HER-2 negative), and that this phenotype was associated with 
poorer OS.27 Consistent with this observation, recently published work by Carey et al28 
suggests that the poorer prognosis basal-like breast tumor phenotype is over-represented in 
premenopausal African American women. Finally, racial differences in the expression of 
cell-cycle regulatory proteins,29–31 as well as differences in steroid-metabolizing genes, have 
been noted.32,33
Can differences in tumor biology explain the poorer OS observed in this study? The lack of 
any significant differences in overall response rates or TTF argues against the predictive 
importance of racial differences in underlying tumor biology in terms of response to 
paclitaxel-based therapies. It is, of course, possible that biologic differences that influence 
survival after disease progression are present, and therefore would not be reflected in lack of 
TTF or response differences. Also, although the hazard of failure was not statistically 
significant and diminished in magnitude and significance in the multivariate model, the 
direction favored an increased hazard of failure for African Americans. Although we feel it 
is unlikely, we cannot rule out the possibility that a true difference in TTF is present.
In terms of survival, a survival disparity remains even after controlling for measured 
differences in tumoral ER status. In addition, the interaction between race and tumoral ER 
status was not of statistical significance for either OS (P = .27) or TTF (P = .47) suggesting 
that survival disparities persisted even when only ER-positive or ER-negative patients were 
considered. Harris et al27 recently published a more detailed analysis of the biologic features 
of the tumors for some of the patients included in this analysis and their relationship to 
disease outcome. Although it might have been interesting to examine the effect that these 
variables had on racial differences in outcome, such a subset analysis would have limited 
statistical power. However, it is possible that accounting for more detailed tumor biology 
information such as grade, HER-2 status or gene-expression classifications would have 
allowed us to explain more of the survival disparity. Of note, in the study by Carey et al, 
African American women with breast cancer continued to have a poorer OS even after 
accounting for differences in proportion of women who had ER-negative and basal-like 
tumors.28
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An area that is receiving increased attention is the impact that underlying comorbidities may 
have in explaining cancer outcome disparities. A recently published study of breast cancer 
patients suggests that African American patients do have higher rates of comorbidities and 
that controlling for them could explain 50% of the survival disparity between African 
Americans and whites.8 In the current study, we were able to account for the combined 
effects of comorbidities and tumor only minimally through an adjustment for performance 
score. Because there was no significant difference in baseline performance status between 
African Americans and whites, it is not surprising that this adjustment had little impact on 
the observed survival disparities. More robust and direct measures of comorbidities may 
have allowed us to explain more of the survival disparity. Although it is true that patients 
with debilitating comorbidities would not have been allowed on these trials, little is known 
about the impact that nonsymptomatic comorbidities such as hypertension, coronary artery 
disease, and diabetes may have on the survival of metastatic breast cancer patients receiving 
chemotherapy. This last explanation points to the need to prospectively collect this 
comorbidity data as part of the clinical trial process.
Additional potentially important prognostic factors such as stage at original diagnosis, year 
of diagnosis, time from original diagnosis to metastatic disease, socioeconomic status, and 
the number of additional lines of therapy administered after patients received per-protocol 
treatment were not incorporated into our models because such information was not reliably 
available. Although we cannot exclude the possibility that such information may have 
modified our results, the combination of the available patient and tumor-related information 
and the standardization of entry criteria, treatment, and follow-up allows for a robust 
analysis of racial differences in outcomes in the metastatic breast cancer setting. We do 
believe, however, that more rigorous collection of this type of information should be 
undertaken in future clinical trial efforts.
Recently, there has been increased focus on the role that toxicity from therapy may play in 
explaining the poorer OS for African American women with breast cancer. Small studies 
have suggested that African Americans have higher rates of neutropenia, take longer to 
complete treatment, receive less intensity of therapy, and are more likely to dropout of 
therapy perhaps as a result of toxicities.12–14 In this study, we examined the issue of toxicity 
in sever always. First we examined baseline values and, consistent with previous reports, we 
found borderline differences in granulocytes and lower median hemoglobin levels among 
African Americans.14,34–36 We then examined the highest rates of grade 3+ toxicity by race 
and found only borderline differences in the incidence of grade 3+ neutropenia and 
thrombocytopenia, but did find fairly significant differences in the incidence of grade3+ 
anemia (hemoglobin < 8.0g/dL). Of note, there was no difference in the hazard of 
developing grade 3+ neutropenia, which suggests no differences in the degree of therapy-
related neutropenia once factors such as study, line of therapy, and time on therapy were 
controlled for. Finally, we hypothesized that, if there was an association between race and 
tolerance of therapy that influenced survival or progression, this would be seen with the 
higher doses of paclitaxel used in the 9342 trial. However, we found no such interaction 
between race and dose of therapy. In the end, we find no evidence of a clinically meaningful 
interaction between race and tolerance of therapy that would explain the survival disparity 
between African Americans and whites reported in this study.
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In conclusion, this study demonstrates a 24% increased risk in the hazard of death for 
African American patients with metastatic breast cancer compared with whites despite 
standardized eligibility and treatment after adjustments for several tumor, patient, and 
treatment-related factors. No significant differences in TTF or tumor response were seen. We 
hypothesize that more direct measures of comorbidities and perhaps other factors such as 
receipt of subsequent therapy could help further explain the observed differences.
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Overall survival by race. Kaplan-Meier analysis of the effect of race on overall survival for 
patients enrolled in Cancer and Leukemia Group B metastatic breast cancer trials 9342 and 
9840. W, white; AA, African American.
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Time to treatment failure by race. Kaplan-Meier analysis of the effect of race on time to 
treatment failure for patients enrolled in Cancer and Leukemia Group B metastatic breast 
cancer trials 9342 and 9840. W, white; AA, African American.
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Table 4






 White 184 24 .80
 African American 42 23
Platelets
 White 5 < 1 .053
 African American 4 2
Hemoglobin
 White 21 3 .0014
 African American 14 8
Granulocytes
 White 267 35 .080
 African American 76 42
Lymphocytes
 White 302 39 .82
 African American 70 38
Infection
 White 41 5 .22
 African American 14 8
Sensory neuropathy
 White 140 18 .89
 African American 34 19
Motor neuropathy
 White 60 8 .95
 African American 14 8
*
White patients, n = 767; African American patients, n = 182.
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